Table 2. NNT to Prevent 1 Adverse Event by Optimizing Lipid-Lowering Therapya.
| Time from index angiography | Death, NNT (95% CI) | Myocardial infarction, NNT (95% CI) | Stroke, NNT (95% CI) | Coronary revascularization, NNT (95% CI) |
|---|---|---|---|---|
| Optimized statin therapy only | ||||
| 1 Year | 280 (211-403) | 284 (238-353) | NA | 144 (84-532) |
| 2 Years | 147 (112-212) | 186 (158-230) | 818 (606-1279) | 56 (48-66) |
| 3 Years | 100 (76-143) | 143 (120-177) | 610 (450-945) | 48 (42-57) |
| 4 Years | 76 (58-110) | 121 (102-149) | 488 (360-767) | 43 (37-51) |
| Optimized statin therapy + ezetimibe | ||||
| 1 Year | 203 (154-291) | 210 (177-260) | NA | 105 (62-383) |
| 2 Years | 108 (82-155) | 139 (119-171) | 603 (449-934) | 42 (36-49) |
| 3 Years | 73 (56-105) | 108 (91-132) | 452 (336-695) | 36 (31-43) |
| 4 Years | 56 (43-81) | 91 (77-112) | 363 (269-565) | 33 (28-38) |
Abbreviations: NA, not applicable because 95% CI spanned 0; NNT, number needed to treat.
a
Data are derived from linear mixed models using 1000 bootstrap samples as described in the Methods section.